Grant: Master's Award: Canada Graduate Scholarships
Université de Montréal
$17,500.00
Exploring the pathophysiology of P3H1 dominant mutation-induced skeletal dysplasia and the therapeutic potential of ER stress reduction
FY 2023-24
Summary
Spondyloepiphyseal dysplasia (SED) is caused by mutations of cartilage proteins, leading to skeletal anomalies and dwarfism. Although the gene P3H1 has never been associated with SED, we recently identified a mono-allelic P3H1 variant in a local patient. P3H1 encodes a protein that contributes to the maturation of collagen in the endoplasmic reticulum (ER) cell compartment, or is alternatively secreted into the extracellular matrix. We believe that the mono-allelic P3H1 variant affects P3H1 conformation, thus yielding its misfolding, its retention in the ER of chondrocytes, the activation of the unfolded protein response (UPR), and subsequent cellular stress and cell death/dysfunction. Indeed, P3H1 is highly secreted in cartilage, and the UPR is a common pathophysiological mechanism in SEDs. Phenylbutyrate (PBA) is an established UPR reducer, used to treat ER stress in several diseases. Therefore, we hypothesize that 1) the pathophysiological mechanism of mono-allelic P3H1 variants leading to SED is UPR activation in chondrocytes, and 2) PBA could potentially alleviate this phenotype. We will test our hypotheses by generating chondrocytes from patient-derived stem cells. Differentiation progress, collagen and P3H1 localization, UPR, autophagy, and apoptosis will be assessed through histological staining, immunocytochemistry, Western blots, and RT-qPCR. As an alternative cellular model, we will overexpress P3H1 in murine chondrogenic cells, later assessed for UPR and protein localization. PBA-treated cells will be assessed in parallel. Lastly, RNA sequencing will help us finish mapping out the dysregulations induced by this novel P3H1-associated SED and their expected correction by our therapeutic candidate.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506093
Name
Hermida Borroto Maria C
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Exploring the pathophysiology of P3H1 dominant mutation-induced skeletal dysplasia and the therapeutic potential of ER stress reduction
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cartilage; Collagen; Er Stress; Genetic Disease; Novel Skeletal Dysplasia; Osteogenesis Imperfecta; P3h1; Phenylbutyrate; Spondyloepiphyseal Dysplasia; Upr
Abstract
Spondyloepiphyseal dysplasia (SED) is caused by mutations of cartilage proteins, leading to skeletal anomalies and dwarfism. Although the gene P3H1 has never been associated with SED, we recently identified a mono-allelic P3H1 variant in a local patient. P3H1 encodes a protein that contributes to the maturation of collagen in the endoplasmic reticulum (ER) cell compartment, or is alternatively secreted into the extracellular matrix. We believe that the mono-allelic P3H1 variant affects P3H1 conformation, thus yielding its misfolding, its retention in the ER of chondrocytes, the activation of the unfolded protein response (UPR), and subsequent cellular stress and cell death/dysfunction. Indeed, P3H1 is highly secreted in cartilage, and the UPR is a common pathophysiological mechanism in SEDs. Phenylbutyrate (PBA) is an established UPR reducer, used to treat ER stress in several diseases. Therefore, we hypothesize that 1) the pathophysiological mechanism of mono-allelic P3H1 variants leading to SED is UPR activation in chondrocytes, and 2) PBA could potentially alleviate this phenotype. We will test our hypotheses by generating chondrocytes from patient-derived stem cells. Differentiation progress, collagen and P3H1 localization, UPR, autophagy, and apoptosis will be assessed through histological staining, immunocytochemistry, Western blots, and RT-qPCR. As an alternative cellular model, we will overexpress P3H1 in murine chondrogenic cells, later assessed for UPR and protein localization. PBA-treated cells will be assessed in parallel. Lastly, RNA sequencing will help us finish mapping out the dysregulations induced by this novel P3H1-associated SED and their expected correction by our therapeutic candidate.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hermida Borroto, Maria C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~